Labcorp Holdings Inc. (LH) has been on a tear, hitting a 52-week high and remaining a strong outperformer in the healthcare sector. The company's upgraded guidance and Q2 results highlights its robust performance, drawing investor interest. Despite some shares being offloaded by Dakota Wealth Management and Park Avenue Securities LLC, the overall investor sentiment is positive. The stock's momentum stems from its strong growth and the performance of its innovative testing sector. Financial results for Q3 2025, scheduled for a pre-market release on October 28, 2025, are eagerly awaited. Major acquisitions, such as buying select assets from BioReference Health's innovative oncology and Clinical Testing Services businesses, have shown Labcorp's continued expansion. Furthermore, the company's FDA-Cleared Alzheimer's Diagnostic Blood Test is now available nationwide, positing it as a frontrunner in diagnostic innovation. However, sales fell below analyst estimates in Q1 earnings, hinting at possible weaknesses. On the brighter side, Q2 earnings and revenues surpassed estimates, pushing the stock up in pre-market. Other notable highlights include the declaration of quarterly dividends and Labcorp's introduction of a novel AI tool called Test Finder to simplify lab test search.
Laboratory Corporation of America Holdings LH News Analytics from Tue, 19 Nov 2024 08:00:00 GMT to Sat, 27 Sep 2025 07:52:19 GMT -
Rating 8
- Innovation 7
- Information 8
- Rumor 3
